Labcorp Holdings Inc (LH)

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal CancerMay 29, 2026 7:00 AM
PR Newswire (US) Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family membersResearch will also assess the clinical impact of broader genetic testing in colorectal cancer careBURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC). The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the impact of multigene panel testing on care for newly diagnosed patients. Leveraging its Invitae testing, Labcorp will serve as the exclusive genetic testing provider, supporting participating sites with its national scale and scientific expertise. Inherited genetic variants contribute to approximately 10% of all colorectal cancer cases. Testing family members of individuals with an inherited cancer-associated variant, called cascade testing, is a well-established approach to cancer prevention—particularly for Lynch syndrome, the most common hereditary colorectal cancer syndrome. However, studies indicate that less than one third of at-risk relatives receive recommended genetic testing.The trial will assess whether proactive outreach by healthcare providers, rather than relying on patients to communicate genetic risk to their relatives, can improve participation of first-degree relatives in cascade genetic testing. In parallel, the trial will assess the impact of multigene panel testing on care for patients newly diagnosed with colorectal cancer."Genetic testing is a critical tool for identifying inherited cancer risk and guiding care for patients and their families, but too often at-risk relatives are not getting tested," said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. "By supporting this trial and serving as the exclusive genetic testing provider, Labcorp is helping generate real-world evidence on how healthcare providers can connect families to genetic testing and follow-up care."The trial is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led and conducted by the Alliance for Clinical Trials in Oncology. It includes participation from the NCI National Clinical Trials Network, which comprises academic medical centers, community oncology health systems and NCI-designated cancer centers. The study is expected to enroll patients and their relatives nationwide, including sites in Puerto Rico."By involving cancer care providers across our network, this study aims to evaluate a practical approach that can strengthen genetic risk identification for patients and their families," noted Frank A. Sinicrope, MD, from the Mayo Clinic and Heather Hampel, MS, CGC, from City of Hope, who are co-lead investigators for the trial. "The findings have the potential to help shape how genetic testing results are communicated to at-risk relatives in patients with colorectal cancer who have hereditary cancer syndromes nationwide."This collaboration reflects Labcorp's continued commitment to advancing genetics-based approaches to improve outcomes for patients with cancer, while supporting high-impact clinical research in collaboration with leading research organizations.For more information on the clinical trial, visit https://clinicaltrials.gov/study/NCT07143487 or view Alliance A212101 at https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FFeatured-TrialsTo learn more about Labcorp's hereditary cancer panels, visit https://www.invitae.com/us/providers/oncology/personalize-cancer-treatmentAbout Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at labcorp.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-supports-multi-institution-trial-to-expand-genetic-testing-in-colorectal-cancer-302785036.htmlSOURCE Labcorp Original: Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over TimeMay 20, 2026 7:00 AM
PR Newswire (US) MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask questions and identify patterns over timeBURLINGTON, N.C., May 20, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp™, an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience. The app is designed to give users additional context about their health and support more informed conversations with healthcare providers. Meeting Demand for Clearer Health Information
As healthcare becomes increasingly consumer-driven, individuals are turning to AI tools to help interpret health information, from understanding lab results to determining next steps in care. According to a Labcorp survey, more than half of consumers (55%) view AI as important for understanding healthcare information, with many already using it to interpret lab results (41%) and understand test ranges (35%). However, many AI tools answer questions in isolation without broader clinical context. MyLabcorp aims to address this gap by enabling users to view their Labcorp test results alongside relevant educational content and AI-generated explanations based on available data over time."Consumers are increasingly turning to AI to help them make sense of their health, but trust and clinical context matter," said Amy Summy, EVP and chief marketing officer at Labcorp. "By bringing together Labcorp's deep scientific expertise with AI, MyLabcorp is designed to help individuals move beyond isolated results to gain deeper insights into their health and support more informed conversations with their healthcare providers."A More Connected, Intuitive Way to Understand Health
Key features of MyLabcorp include:Lab results over time – Users have access to their Labcorp test results in a mobile-friendly view that tracks trends over time.AI-enabled insights – Users can chat with an AI assistant for real-time, personalized explanations of lab results and lifestyle considerations based on available Labcorp test data. MyLabcorp's AI capabilities are powered in part by OpenAI's advanced reasoning models, enabling more natural, conversational interactions tailored to each user.Health education content – Users can explore clinically reviewed, guideline-based information across key health areas, including cardiometabolic health, mental health, digestion, kidney function and sexual health, integrated with lab results to show trends and provide additional context.Lab services and support – Users can view and schedule appointments, locate patient service centers, access results, shop for tests and manage billing.Secure, trusted experience – A HIPAA-compliant platform built to protect personal health information and user data."At Labcorp, we're investing in advanced technology and AI to make diagnostic insights more accessible, personalized and actionable, improving how people understand and manage their health," said Bola Oyegunwa, Ph.D., EVP and chief information and technology officer at Labcorp. "MyLabcorp reflects this approach by combining Labcorp's scientific expertise with OpenAI's models to help individuals better understand their results and identify patterns over time, all within a secure, trusted environment."Availability of MyLabcorp1
MyLabcorp is now available in the Apple App Store and Google Play Store with additional features rolling out on an ongoing basis.To learn more, visit https://www.labcorp.com/patients/mylabcorpAbout Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of MyLabcorp.Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."____________________________1MyLabcorp is designed to support understanding and wellness and does not provide medical diagnoses or treatment recommendations. Always consult a qualified healthcare professional with medical questions or concerns. View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-mylabcorp-a-new-ai-powered-mobile-app-designed-to-help-consumers-understand-lab-results-and-track-health-trends-over-time-302777006.htmlSOURCE Labcorp Original: Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health SystemsMay 12, 2026 7:00 AM
PR Newswire (US) Labcorp's full test menu will be available through Epic's Aura platformIntegration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through AuraCollaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwideBURLINGTON, N.C., May 12, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems. Through the collaboration, Labcorp's full test menu will be available through Aura, Epic's unified platform for ordering and receiving lab results. The integration will drive meaningful operational efficiencies, streamline lab ordering for clinicians and care teams, and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide. Reducing Complexity and Expanding Access to Testing and Diagnostic Innovation
Health systems often face lengthy, complex and time-consuming IT projects to integrate with laboratory partners. By leveraging Epic's Aura, the expansion will reduce the time, cost and ongoing maintenance typically required for lab interfaces. Building on the availability of Invitae genetic tests through Aura, part of Labcorp's diagnostic portfolio, health systems will be able to access Labcorp's full test menu and new tests as they are introduced directly within their existing Epic workflows."This expanded collaboration reflects how Labcorp is investing to meet the evolving needs of hospitals and health systems," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By simplifying lab integrations and delivering our full test menu directly within Epic workflows, we are expanding access and building a strong foundation for continued innovation."Benefits for Clinicians and Health Systems
The expanded integration will deliver meaningful benefits including:Simplified onboarding and maintenance – Aura's connectivity and content-management capabilities reduce the effort required to onboard and maintain Labcorp's test menu, reducing integration complexity for hospitals and health systems.Seamless access within Epic workflows – Clinicians will be able to order Labcorp tests and receive discrete results directly within their Epic workflow, improving efficiency and reducing reliance on manual processes or workarounds.Broader access to Labcorp's full and evolving test menu, including new and advanced diagnostics."Expanding Labcorp's use of Aura to include its full test menu makes it easy for clinicians to order the right test the first time, right from their workflow, so patients get accurate answers faster," said Sumit Rana, President of Epic.To learn more about Labcorp's ongoing collaboration with Epic and future plans to advance diagnostic integration for hospitals and health systems, visit https://www.labcorp.com/organizations/epic. About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of integrating Labcorp's full test menu into the Epic Aura platform.Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS." View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-and-epic-expand-collaboration-to-advance-diagnostic-integration-across-hospitals-and-health-systems-302768704.htmlSOURCE Labcorp Original: Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 GuidanceApril 30, 2026 6:50 AM
PR Newswire (US)

Results from Operations for first quarter 2026 versus first quarter 2025:Revenue: $3.54 billion vs. $3.35 billion, up 5.8%Diluted EPS: $3.35 vs. $2.52, up 32.8%Adjusted EPS: $4.25 vs. $3.84, up 10.6%Raised Full-Year Enterprise Revenue and Adjusted EPS guidance:Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpointAdjusted EPS range of $17.70 to $18.35; up 13 cents at the midpointAdvanced leadership in specialty and companion diagnostics and expanded strategic health systems collaborationsCollaborated with Optum.ai to enhance patient and provider experienceBURLINGTON, N.C., April 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2026 and updated full-year guidance.







"Labcorp delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our Diagnostics and Central Laboratory businesses," said Adam Schechter, Chairman and CEO of Labcorp. "Health systems, providers, consumers, and biopharmaceutical customers are increasingly turning to Labcorp as their partner of choice for their complex, innovative testing needs. Our investments in advanced technologies, including robotics and AI, are improving the customer experience and transforming the way we operate. Driven by continued progress across our strategic priorities, we are raising our full year Adjusted EPS guidance to $18.03 at the midpoint of the range, an increase of $0.13."Labcorp continues to advance its strategic priorities:Be a partner of choice for health systems and regional and local laboratories:Announced a nationwide strategic collaboration with Children's Hospital of Philadelphia (CHOP) to expand access to cutting-edge diagnostics for pediatric patients.Completed the acquisition of select assets of Crouse Health's Laboratory Alliance of Central New York and executed an agreement with Crouse Health to manage their inpatient labs.Lead in specialty testing:Announced a collaboration with Illumina to expand access to advanced genomic testing in oncology to deliver more precise biomarker insights.Expanded nationwide access to the first FDA-approved companion diagnostic that helps identify patients with platinum-resistant ovarian cancer who may benefit from Merck's KEYTRUDA® and KEYTRUDA QLEX™.Launched the Labcorp Fentanyl Visual Urine Test, an FDA-cleared rapid screening test that delivers results in just 10 minutes and assesses possible fentanyl exposure for up to 48 hours.Shape our future through technology and innovation:Launched an AI-powered, real-world data platform with Amazon Web Services (AWS) and Datavant to accelerate Alzheimer's research.Expanded a collaboration with PathAI to deploy AISight® Dx, an FDA-cleared digital pathology platform.Announced a collaboration with Optum.ai to apply AI capabilities to streamline laboratory operations, improve efficiency, and enhance the patient and provider experience.Drive personalized health solutions:Grew Consumer Health and expanded the Labcorp OnDemand test portfolio with new tests for insulin resistance and pancreatic function, as well as customizable men's and women's health tests.In May, the company will launch MyLabcorp, a secure, AI-powered mobile app that brings an individual's test results and health data together with clinical guidance to help consumers better understand their test results.Labcorp also remains committed to a disciplined allocation of capital. In the first quarter of 2026, the company invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid out $61.2 million in dividends. On April 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on June 11, 2026, to stockholders of record at the close of business on May 29, 2026.LABCORP HOLDINGS INC. AND SUBSIDIARIESCONSOLIDATED RESULTS

Three Months Ended March 31,
2026
2025
Delta





Revenue Summary (Dollars in billions)




Total Revenue$     3.54
$     3.35
5.8 %Organic(1)



3.1 %Acquisitions, net of Divestitures(2)



1.4 %Foreign Exchange



1.3 %





(1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.(2) Includes the impact from strategic actions taken in Early Development.
Earnings Summary (Dollars in millions, except per share data)




Operating Income ("OI")$   380.8
$   326.0

OI as % of Revenue10.8 %
9.7 %
100 bps





Adjustments (3)$   127.1
$   143.0







Adjusted Operating Income  ("AOI") (4)$   507.9(5)$   469.0

AOI as % of Revenue14.4 %(5)14.0 %
30 bps





Net Earnings Attributable to Labcorp Holdings Inc.$   277.8
$   212.8

Diluted EPS$     3.35
$     2.52

Adjusted EPS (4)$     4.25
$     3.84
10.6 %





(3) Adjustments include amortization, impairment charges, restructuring charges, and special items.(4) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.(5) The increase in adjusted operating income and margin was primarily driven by organic growth. LABCORP HOLDINGS INC. AND SUBSIDIARIESCONSOLIDATED RESULTS




Three Months Ended March 31,
2026
2025Cash Flow Summary (Dollars in millions)






Operating Cash Flow$         191.5
$           18.5Capital Expenditures121.0
126.0Free Cash Flow$          70.5(1)$        (107.5)



(1) The increase in free cash flow was primarily driven by higher cash earnings.Capital Allocation SummaryAt the end of the quarter, Labcorp's cash and cash equivalents balance was $981.1 million and total debt was $6.33 billion. These higher cash and debt balances are due to the pre-funding of maturing debt.During the quarter, the company invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid out $61.2 million in dividends.LABCORP HOLDINGS INC. AND SUBSIDIARIESDiagnostics Laboratories Segment Summary

Three Months Ended March 31,
2026
2025
DeltaRevenue Summary (Dollars in billions)



Total Revenue$    2.76
$    2.63
5.0 %Organic



2.9 %Acquisitions, net of Divestitures



2.0 %Foreign Exchange



0.2 %











Earnings Summary (1) (Dollars in millions)



Adjusted Operating Income ("AOI") (2)$   458.7(3)$   427.5

AOI as % of Revenue16.6 %(3)16.3 %
30 bps





(1) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.(2) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.(3) Adjusted operating income and margin increased primarily driven by organic growth, despite the impact from adverse weather. 

Three Months Ended March 31, 2026

Requisition
Price/Mix

Volume Delta (4)
Delta (4)Metrics Summary



Total
2.5 %
2.6 %Organic (5)
1.1 %(6)1.8 %Acquisitions, net of Divestitures
1.4 %
0.6 %Foreign Exchange
— %
0.2 %




(4) Column shows changes versus the three months ended March 31, 2025.(5) Organic price/mix includes lab management agreements. (6) Includes the impact from adverse weather. LABCORP HOLDINGS INC. AND SUBSIDIARIESBiopharma Laboratory Services Segment Summary


Three Months Ended March 31,


2026
2025
Delta
Revenue Summary (Dollars in millions)




Total Revenue
$   780.6
$   721.3
8.2 %(1)Organic(2)




3.7 %
Acquisitions, net of Divestitures(3)




(1.0) %
Foreign Exchange




5.5 %








(1) Central Labs revenue growth of 11.3% and Early Development revenue growth of 0.6%.(2) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.(3) Includes the impact from strategic actions taken in Early Development.







Earnings Summary (4) (Dollars in millions)




Adjusted Operating Income ("AOI") (5)
$   120.7(6)$   106.9


AOI as % of Revenue
15.5 %(6)14.8 %
60 bps








(4) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.(5) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.(6) Adjusted Operating Income and margin increased driven by growth in Central Labs.
As of

March 31, 2026
Metrics Summary (Dollars in billions)

TTM Net Orders$           3.29
TTM Book to Bill1.04
Backlog$           8.64(7)Next Twelve Months Forecast Backlog Conversion$           2.69



(7) Backlog increased 5.6% compared to this period last year.Guidance for 2026Labcorp is updating 2026 full year guidance to reflect its first quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of March 31, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.(Dollars in billions, except per share data)





Previous
Updated

2026 Guidance
2026 Guidance

Low
High
Low
HighRevenue







Labcorp Enterprise (1)(2)
$14.61
$14.79
$14.65
$14.80Growth (3)
4.7 %
6.0 %
5.0 %
6.1 %








Diagnostics Laboratories
$11.42
$11.53
$11.43
$11.52Growth (3)
5.0 %
6.0 %
5.1 %
5.9 %








Biopharma Laboratory Services (4)
$3.19
$3.25
$3.22
$3.27Growth (3)
3.0 %
5.0 %
3.8 %
5.4 %








Adjusted EPS
$17.55
$18.25
$17.70
$18.35








Free Cash Flow
$1.24
$1.36
$1.24
$1.36(1) 2026 Updated guidance includes an impact from foreign currency translation of 0.4%.(2) Enterprise level revenue is presented net of intercompany transaction eliminations.(3) Growth based on 2025 Enterprise revenue of $14.0 billion, Diagnostics revenue of $10.9 billion, and Biopharma Laboratory Services revenue of $3.1 billion.(4) 2026 Updated guidance includes an impact from foreign currency translation of 1.5%.Use of Adjusted MeasuresThe company has provided in this press release and accompanying tables "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company's operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company's financial results with the financial results of other companies. However, the company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and an identification of the components that comprise "special items" used for certain adjusted financial information are included in the tables accompanying this press release.The company today is providing an investor relations presentation with additional information on its business and operations, which is available in the investor relations section of the company's website at https://ir.labcorp.com. Analysts and investors are directed to the website to review this supplemental information.A webcast discussing Labcorp's quarterly results will be held today at 9:00 a.m. ET and is available by accessing the Labcorp investor relations website and navigating to the "Events" section. Alternatively, the live webcast can be accessed on this link. This webcast will be archived and accessible for one year.About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including global economic and market conditions  on the company's businesses, operating results, cash flows and/or financial condition, (iii) future business  strategies, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions and partnerships, and (v) opportunities for future growth.Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company's former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failure of the company's information technology, systems, or data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward- looking statements.The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".- End of Text -
- Tables to Follow -LABCORP HOLDINGS INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS(In Millions, Except Per Share Data)

Three Months Ended March 31,
2026
2025Revenues$       3,537.6
$       3,345.1Cost of revenues2,523.8
2,397.1Gross profit1,013.8
948.0Selling, general, and administrative expenses551.0
546.0Amortization of intangibles and other assets75.6
69.6Restructuring and other charges6.4
6.4Operating income380.8
326.0Other (expense) income:


Interest expense(55.1)
(56.0)Investment income12.2
6.5Equity method loss, net(5.1)
(0.3)Other, net(13.1)
(1.0)Earnings from operations before income taxes319.7
275.2Provision for income taxes41.7
62.2Net earnings278.0
213.0Less: Net earnings attributable to the noncontrolling interest(0.2)
(0.2)Net earnings attributable to Labcorp Holdings Inc.$         277.8
$         212.8



Earnings per common share:


Basic earnings per common share$           3.37
$           2.54Diluted earnings per common share$           3.35
$           2.52



Weighted-average basic common shares outstanding82.3
83.6Weighted-average diluted common shares outstanding82.9
84.3 LABCORP HOLDINGS INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In Millions)

March 31, 2026
December 31, 2025ASSETS


Current assets:


Cash and cash equivalents$               981.1
$               532.3Accounts receivable, net2,288.6
2,103.8Unbilled services, net161.9
156.9Supplies inventory497.7
534.7Prepaid expenses and other629.5
692.8Total current assets4,558.8
4,020.5Property, plant, and equipment, net3,065.5
3,081.5Goodwill, net6,955.2
6,789.5Intangible assets, net3,636.1
3,596.0Joint venture partnerships and equity method investments146.6
153.9Other assets, net724.9
751.3Total assets$           19,087.1
$           18,392.7LIABILITIES AND SHAREHOLDERS' EQUITY


Current liabilities:


Accounts payable$               695.7
$               840.8Accrued expenses and other851.9
847.8Unearned revenue405.2
439.1Short-term operating lease liabilities183.2
191.1Short-term finance lease liabilities4.6
4.6Short-term borrowings and current portion of long-term debt500.4
500.1Total current liabilities2,641.0
2,823.5Long-term debt5,833.7
5,084.6Operating lease liabilities656.5
682.6Finance lease liabilities62.2
63.0Deferred income taxes and other tax liabilities456.4
454.5Other liabilities691.8
647.8Total liabilities10,341.6
9,756.0Commitments and contingent liabilities


Noncontrolling interest16.9
16.9Shareholders' equity:


Common stock, 82.3 and 82.2 shares outstanding at March 31, 2026, and
December 31, 2025, respectively7.4
7.5Additional paid-in capital—
—Retained earnings8,784.4
8,639.9Accumulated other comprehensive loss(63.2)
(27.6)Total shareholders' equity8,728.6
8,619.8Total liabilities and shareholders' equity$           19,087.1
$           18,392.7 LABCORP HOLDINGS INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(In Millions)

Three Months Ended March 31,
2026
2025CASH FLOWS FROM OPERATING ACTIVITIES:


Net earnings$         278.0
$         213.0Adjustments to reconcile net earnings to net cash provided by operating activities:


Depreciation and amortization173.3
166.8Stock compensation31.7
32.8Operating lease right-of-use asset expense48.0
48.6Deferred income taxes2.0
(6.1)Other, net11.4
8.1Change in assets and liabilities (net of effects of acquisitions and divestitures):


Increase in accounts receivable(187.9)
(170.8)(Increase) decrease in unbilled services(6.2)
3.9Decrease in supplies inventory35.4
8.4Decrease in prepaid expenses and other4.0
45.0Decrease in accounts payable(138.7)
(147.6)Decrease in unearned revenue(32.1)
(8.9)Decrease in accrued expenses and other(27.4)
(174.7)Net cash provided by operating activities191.5
18.5CASH FLOWS FROM INVESTING ACTIVITIES:


Capital expenditures(121.0)
(126.0)Proceeds from sale of assets7.8
0.5Purchase of equity affiliates or other investments(6.7)
(157.0)Acquisition of businesses, net of cash acquired(202.2)
(53.5)Net cash used for investing activities(322.1)
(336.0)CASH FLOWS FROM FINANCING ACTIVITIES:


Proceeds from term loan750.0
—Payments on senior notes—
(1,000.0)Proceeds from accounts receivable securitization—
225.0Proceeds from revolving credit facilities—
64.8Payments on revolving credit facilities—
(64.8)Net share settlement tax payments from issuance of stock to employees(39.8)
(25.5)Net proceeds from issuance of stock to employees32.9
25.7Dividends paid(61.2)
(61.6)Purchase of common stock(98.0)
—Other, net(3.4)
(3.3)Net cash provided by (used for) financing activities580.5
(839.7)Effect of exchange rate on changes in Cash and cash equivalents(1.1)
7.9Net increase (decrease) in Cash and cash equivalents448.8
(1,149.3)Cash and cash equivalents at beginning of period532.3
1,518.7Cash and cash equivalents at end of period$         981.1
$         369.4 LABCORP HOLDINGS INC. AND SUBSIDIARIESCondensed Combined Non-GAAP Segment Information(Dollars in Millions)

Three Months Ended March 31,
2026
2025Diagnostics Laboratories


Revenues$     2,762.1
$     2,629.6



Adjusted operating income$        458.7
$        427.5Adjusted operating margin16.6 %
16.3 %



Biopharma Laboratory Services


Revenues$        780.6
$        721.3



Adjusted operating income$        120.7
$        106.9Adjusted operating margin15.5 %
14.8 %



Consolidated


Revenues$     3,537.6
$     3,345.1



Adjusted segment operating income$        579.4
$        534.4Unallocated corporate expense(71.5)
(65.4)Consolidated adjusted operating income$        507.9
$        469.0Adjusted operating margin14.4 %
14.0 %The consolidated revenue and adjusted segment operating income are presented net of intercompany transaction eliminations and other amounts not used in determining segment performance. Adjusted operating income and adjusted operating margin are non-GAAP measures. See the subsequent reconciliation of non-GAAP financial measures.LABCORP HOLDINGS INC. AND SUBSIDIARIESReconciliation of Non-GAAP Measures(Dollars and Shares in Millions, Except Per Share Data)


Three Months Ended March 31,

2026
2025Adjusted Operating Income



Operating income
$         380.8
$         326.0Amortization of intangibles and other assets (a)
75.6
69.6Restructuring and other charges (b)
6.4
6.4Acquisition and disposition-related costs (c)
9.9
29.1Launchpad costs (d)
13.0
20.1Other
22.2
14.5TSA reimbursement (e)
—
3.3Adjusted operating income
$         507.9
$         469.0




Adjusted operating profit margin
14.4 %
14.0 %




Adjusted Net Income



Net income
$         277.8
$         212.8Impact of adjustments to operating income
127.1
143.0Loss on venture fund investments, net (f)
7.1
3.4Equity method loss from SYNLAB investment (g)
5.0
—TSA reimbursement (e)
—
(3.3)Other
(8.5)
—Income tax impact of adjustments (h)
(56.1)
(31.9)Adjusted net income
$         352.4
$         324.0




Weighted-average diluted common shares outstanding
82.9
84.3




Adjusted net income per share
$          4.25
$          3.84(a)Amortization of intangible assets acquired as part of business acquisitions.(b)Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions and facilities and contract termination costs within the organization in connection with our LaunchPad initiatives, and acquisitions or dispositions of businesses by the company.(c)Acquisition and disposition-related costs include due-diligence legal and advisory fees, retention bonuses, impact of delayed contract or license transfers, and other integration or disposition related activities.(d)LaunchPad costs include non-capitalized costs associated with the implementation of systems, consolidation of processes, and consulting costs incurred as part of various business process improvement initiatives.(e)Represents transition services fees charged to Fortrea Holdings Inc. related to administrative and IT systems support.  The costs to provide these services are included in operating income but the service fees are included in other income.(f)The company makes investments in companies or investment funds developing promising technology related to its operations. The company recorded net gains and losses related to several distributions from venture funds, increases in the market value of investments, and impairments of other investments due to the underlying performance of the investments.(g)Adjustment removes the impact of the equity method income from the Company's minority investment in SYNLAB.(h)Income tax impact of adjustments calculated based on the tax rate applicable to each item. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-2026-first-quarter-results-raises-full-year-2026-guidance-302757998.htmlSOURCE Labcorp Holdings Inc

Original: Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®April 22, 2026 7:00 AM
PR Newswire (US)

BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii







Helping Patients Access Critical New Treatment Options
Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and poor survival outcomes. The approval of KEYTRUDA and KEYTRUDA QLEX in this setting introduces meaningful new treatment options that have been found to reduce the risk of disease progression and improve overall survival.iii Labcorp's nationwide availability of PD-L1 IHC 22C3 pharmDx enables clinicians to quickly identify patients who may benefit from these newly approved treatments."Platinum-resistant ovarian cancer is incurable, and current treatment options offer limited and short-lived benefits for patients—making it one of the most challenging forms of the disease to treat," said Dr. Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp. "By making this companion diagnostic available nationwide, Labcorp is helping clinicians rapidly identify eligible patients and connecting them with a therapy that offers new hope."Supporting Early Access Following FDA Approvals
Following the FDA's February approval of KEYTRUDA and KEYTRUDA QLEX alongside PD-L1 IHC 22C3 pharmDx,ii Labcorp participated in Agilent Technologies' Early Validation Program to help support rapid testing availability. Through standardized training and readiness activities, Labcorp was prepared to expand nationwide access quickly following approval.For more information about Labcorp's Oncology solutions, contact us at https://oncology.labcorp.com/contact-us.About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.KEYTRUDA® is a registered trademark and KEYTRUDA QLEX™ is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USAiThe FDA approved the PD-L1 IHC 22C3 pharmDx test from Agilent Technologies as a companion diagnostic that detects PD-L1 expression in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), and is indicated as an aid in identifying patients for treatment with KEYTRUDA, Merck's anti-PD-1 therapy.iiThe FDA simultaneously approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] ≥1), as determined by an FDA-authorized test, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma, who have received one or two prior systemic treatment regimens.iiiThe Phase 3 KEYNOTE-B96 (ENGOT-ov65) trial showed KEYTRUDA plus paclitaxel, with or without bevacizumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), the trial's primary endpoint, and overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 (CPS ≥1) compared to placebo plus paclitaxel, with or without bevacizumab.



View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-fda-approved-companion-diagnostic-to-identify-patients-with-ovarian-cancer-eligible-for-keytruda-302749466.htmlSOURCE Labcorp

Original: Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®

Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 MinutesApril 15, 2026 7:00 AM
PR Newswire (US)

First FDA-cleared rapid fentanyl test of its kind made in the United States designed to help emergency department and hospital teams act quickly when every second countsFentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX DiagnosticsBURLINGTON, N.C., April 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Labcorp Fentanyl Urine Visual Test, the first U.S. Food and Drug Administration (FDA)-cleared rapid fentanyl test of its kind manufactured in the United States. The test delivers results in just 10 minutes, giving healthcare providers fast, actionable answers when treating suspected fentanyl exposure in emergency departments, hospitals and clinics.







Fentanyl exposure remains a concern across acute care and clinical settings. Labcorp data show that between 2024 and 2025, approximately 4% of pre-employment screenings tested positive for fentanyl, and nearly 10% of patients receiving opioid use disorder treatment tested positive. Recent guidance from the Association for Diagnostics and Laboratory Medicine (ADLM) also highlights the importance of reliable screening tools in emergency care, particularly as synthetic opioids like fentanyl become more prevalent."When clinicians suspect fentanyl exposure, they need quick, dependable answers to inform care," said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. "The Labcorp Fentanyl Urine Visual Test delivers results in minutes, helping teams respond quickly and confidently in emergency departments, hospitals and clinics—ultimately supporting better patient outcomes."Features of the Labcorp Fentanyl Urine Visual Test
The test assesses fentanyl exposure by detecting norfentanyl, the primary fentanyl metabolite, which can remain present in urine up to 48 hours after initial exposure. This provides a longer detection window than fentanyl itself, which may clear within hours. The test is FDA-cleared for use by qualified professionals in Clinical Laboratory Improvement Amendments (CLIA)-certified settings. Results are intended for preliminary rapid screening purposes and should be confirmed using appropriate laboratory methods, per the standard practice for rapid testing.Introducing Labcorp Point of Care
The Labcorp Fentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX Diagnostics. Throughout 2026, product names, packaging and resources will transition from MEDTOX Diagnostics to Labcorp Point of Care.For more information on the Labcorp Fentanyl Urine Visual Test, visit pointofcare.labcorp.com/fentanyl-test.About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and perform more than 750 million tests annually for patients around the world. Learn more at www.labcorp.com.



View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-fda-cleared-fentanyl-test-delivering-results-in-10-minutes-302742562.htmlSOURCE Labcorp

Original: Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes

Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's ResearchApril 14, 2026 7:00 AM
PR Newswire (US)

Platform leverages agentic AI and diverse healthcare datasets to transform and speed drug developmentBURLINGTON, N.C., April 14, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster. Developed with Amazon Web Services (AWS) and Datavant, the platform provides access to large, diverse datasets and advanced analytics—using deidentified, privacy-protected healthcare data—designed to accelerate scientific discovery, shorten drug development timelines and improve identification of patients for clinical trial recruitment. The platform enables researchers, biopharma companies, payors and contract research organizations to generate insights in minutes that previously required months of intensive data mining.







With more than 7.2 million Americans living with Alzheimer's disease and annual care costs exceeding $380 billion in the U.S., accelerating drug development is critical. Traditionally, fragmented data and lengthy data preparation have slowed progress. Labcorp's platform addresses these challenges by leveraging standardized, direct-from-source laboratory data captured across millions of patients and advanced AI models to streamline data access and analysis. As a leader in neurology diagnostics, Labcorp offers the broadest blood-based biomarker testing portfolio for Alzheimer's disease and dementia, generating data that uniquely inform the depth, quality and scale of insights generated through this platform."This platform represents a powerful acceleration in Alzheimer's research," said Bola Oyegunwa, Ph.D., Labcorp's EVP and chief information and technology officer. "By combining AI, advanced analytics and the scale of Labcorp's diagnostic data, we're redefining what's possible—compressing months of manual data preparation into minutes. That shift enables researchers to focus on discovery instead of data engineering, accelerating the insights needed to drive better treatment decisions. Ultimately, this platform is about improving patient outcomes and delivering answers and hope faster for the millions of patients and families waiting for progress."The platform represents a breakthrough in unifying healthcare research, combining Labcorp's extensive diagnostic and genomic datasets with medical claims, and, in future versions, electronic health record and social determinants of health data. Powered by advanced AI analytics, the platform can quickly identify patient cohorts, track disease progression patterns and measure treatment effectiveness across diverse populations.Dr. Rowland Illing, chief medical officer and director, Healthcare and Life Sciences at AWS, emphasized the platform's transformative potential, "This collaboration between Labcorp and AWS shows how AI can help reduce the time from hypothesis to actionable insight from months to minutes, potentially shaving years off the drug development process. By leveraging AWS's AI services, including Amazon Bedrock to power the platform's agents and Amazon SageMaker for analyzing clinical trial and patient datasets, we're fundamentally changing the scope and scale of insights researchers can generate."The platform's AI-powered analytics interface offers:Real-time, population-level analysis of treatment patterns, effectiveness and patient outcomes across diverse populationsCharacterization of patient segments tested for Alzheimer's diseaseSupport for the selection of deidentified patient cohorts suitable for clinical trial recruitment based on defined inclusion and exclusion criteriaAdvanced statistical modeling tools to identify patient cohorts with unmet clinical needThe platform will complete its initial validation phase in spring 2026 and is expected to expand through 2026, incorporating additional data sources and analytical capabilities to further accelerate research insights including inflammatory diseases, cardiometabolic conditions, women's health and oncology.This innovation extends Labcorp's broader real-world data strategy, leveraging AWS's AI-powered analytics and Datavant's privacy-preserving connectivity to enable secure, scalable analysis of de-identified healthcare data.To learn more about Labcorp's AI-powered real-world data platform, visit https://www.labcorp.com/biopharma/real-world-data-solutions/ai-platform/alzheimersAbout Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of Labcorp's real-world data platform for Alzheimer's disease research.Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."










View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-introduces-ai-powered-real-world-data-platform-with-aws-and-datavant-to-accelerate-alzheimers-research-302741607.htmlSOURCE Labcorp

Original: Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research

Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics NationwideApril 13, 2026 8:30 AM
PR Newswire (US)

Collaboration aims to speed the discovery, development and national availability of specialized pediatric diagnosticsBURLINGTON, N.C. and PHILADELPHIA, April 13, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Children's Hospital of Philadelphia (CHOP), the nation's first pediatric hospital, announced today a strategic collaboration to accelerate the discovery, development and nationwide availability of specialized pediatric diagnostics. By combining CHOP's pediatric research and clinical expertise with Labcorp's national diagnostic infrastructure, scientific capabilities and commercialization expertise, the collaboration aims to expand access to advanced diagnostic testing for children and families across the country.







"Our shared aim to improve children's health makes this collaboration so powerful," said Stephen R. Master, M.D., Ph.D., division chief and director of metabolic and advanced diagnostics at Children's Hospital of Philadelphia. "By pairing CHOP's pediatric leadership with Labcorp's nationwide reach, we seek to deliver important new and specialized tests to children and their families more efficiently and at greater scale."Innovation Pipeline to Advance Pediatric Diagnostic Development
At the core of the collaboration is the creation of a joint pediatric diagnostics innovation pipeline where CHOP and Labcorp will team up to identify, develop and expand new tests and technologies with a goal of streamlining the path from discovery to national availability. Pediatric-specific diagnostics deliver more accurate, age-appropriate insights for children by accounting for their unique biology, developmental stages and physiological ranges—factors that traditional adult-oriented tests often overlook. The collaboration will make novel diagnostics available nationwide across key clinical areas, such as oncology, metabolic disease and autoimmune conditions.Expanding Nationwide Access to Advanced Pediatric Testing
Together, the organizations will provide clinicians and health systems with cutting-edge pediatric testing—bringing breakthrough diagnostics in cancer, genetics, immune disorders and rare diseases to patients sooner and enabling earlier, more precise diagnoses."Labcorp and CHOP share a commitment to advancing pediatric care. By combining CHOP's deep pediatric expertise with Labcorp's scientific capabilities and national reach, we can bring pediatric diagnostic innovations to patients faster and make advanced testing accessible to many more families," said Bryan Vaughn, executive vice president, Diagnostics at Labcorp."Today's announcement marks an important milestone at the intersection of scientific research and collaboration," said Joseph Mitchell, M.D., president at Children's Hospital of Philadelphia. "Our commitment to innovation has always been driven by one goal: improving the lives of children. By working closely with Labcorp, we can create the breakthroughs that children and families need – today and in the years to come."About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.comAbout Children's Hospital of Philadelphia 
A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center), and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit https://www.chop.edu.Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the collaboration between Labcorp and Children's Hospital of Philadelphia.Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond Labcorp's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement its business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in Labcorp's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 



View original content to download multimedia:https://www.prnewswire.com/news-releases/childrens-hospital-of-philadelphia-and-labcorp-announce-a-collaboration-to-accelerate-access-to-advanced-pediatric-diagnostics-nationwide-302740400.htmlSOURCE Labcorp

Original: Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide

Labcorp Declares Quarterly DividendApril 9, 2026 6:50 AM
PR Newswire (US)

BURLINGTON, N.C., April 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026.







About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.



View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-declares-quarterly-dividend-302737261.htmlSOURCE Labcorp Holdings Inc

Original: Labcorp Declares Quarterly Dividend

Labcorp to Announce First Quarter Financial Results on April 30, 2026March 31, 2026 4:15 PM
PR Newswire (US)

BURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A link to the earnings webcast will also be available on the investor relations website.







A replay of the webcast will be available on the "News & Events" section of the investor relations website approximately two hours after the conclusion of the live event and will be available for one year.About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at https://www.labcorp.com/.



View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-to-announce-first-quarter-financial-results-on-april-30-2026-302730362.htmlSOURCE Labcorp Holdings Inc

Original: Labcorp to Announce First Quarter Financial Results on April 30, 2026

Illumina and Labcorp expand collaboration to broaden access to precision oncology testingMarch 18, 2026 9:15 AM
PR Newswire (US)

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need."By deepening our collaboration, we'll continue to leverage the strengths of our respective teams to innovate and improve access to critical biomarker testing for patients with cancer," said Traci Pawlowski, vice president of Clinical Product Development at Illumina. "Our longstanding collaboration is rooted in a shared vision to advance precision oncology through groundbreaking research and leading-edge technologies."New test development is expected to span advanced oncology research and in vitro diagnostic (IVD) tests for comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS). These solutions will aim to address areas of unmet needs in precision oncology and help bridge existing testing gaps.As part of the collaboration, the companies will explore co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive for solid tumor profiling. Together, these distributed IVD test kits are intended to expand access to both tissue and liquid biopsy testing for hospitals and community health systems—bringing advanced biomarker testing closer to patients and helping to provide more specific diagnoses and identify eligibility for targeted treatments and clinical trials. This distributed offering also aims to provide pharmaceutical companies with differentiated opportunities for companion diagnostic (CDx) development, supporting both tissue and liquid biopsy needs for targeted therapy approvals."This collaboration reflects Labcorp and Illumina's shared commitment to improving cancer care through innovation and access," said Shakti Ramkissoon, MD, PhD, MBA, vice president and medical lead for oncology at Labcorp. "Building on our longstanding medical and scientific collaborations and our ongoing efforts to generate clinical evidence and expand access to advanced genomics, we are combining our expertise to deliver transformative testing solutions that support more timely, equitable cancer care."Illumina and Labcorp will also continue joint efforts to demonstrate the clinical utility of CGP and promote its adoption. In a collaborative study published in Frontiers of Oncology, researchers evaluated more than 7,600 non-small cell lung cancer (NSCLC) tumor samples. The study applied Illumina CGP to demonstrate its coverage and utility in detecting known and novel genomic features of NSCLC. Results showed that CGP detected variants with a current targeted therapy or clinical trial in more than 72% of patient tumors.This is one of eight joint publications in oncology between Illumina and Labcorp since 2022, along with 18 posters and presentations made at industry conferences."Expanding access to advanced genomic testing is essential to delivering personalized cancer care," said Pawlowski. "Together with Labcorp, we are accelerating innovation to bring critical insights closer to patients and enable better outcomes across diverse care settings."Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in researching, developing and launching new technologies; (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners,  together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.Contacts Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia:
Christine Douglass
PR@illumina.com



View original content:https://www.prnewswire.com/news-releases/illumina-and-labcorp-expand-collaboration-to-broaden-access-to-precision-oncology-testing-302716715.htmlSOURCE Illumina, Inc.

Original: Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform NationwideFebruary 23, 2026 7:00 AM
PR Newswire (US)

AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient careBURLINGTON, N.C., Feb. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations. The cloud-based technology allows pathologists to view and manage slides digitally and use AI to support key steps in the diagnostic process.







"Labcorp is committed to building a modern, AI-powered infrastructure that sets a new standard for efficiency, collaboration and innovation in pathology," said Dr. Marcia Eisenberg, chief scientific officer at Labcorp. "PathAI's technology allows us to scale digital pathology nationwide and integrate AI insights into routine care—delivering faster, more consistent results for patients and providers."Labcorp will deploy AISight Dx across its anatomic pathology labs and hospital collaborations, enabling fully digital workflows for case management, slide review, collaboration and annotation. The platform also integrates AI-powered image analysis, secure storage and system connectivity to deliver faster turnaround, greater efficiency, reliable quality and improved collaboration. Labcorp will also incorporate digital pathology workflows in support of its precision medicine products."Labcorp's leadership in diagnostics makes them an ideal partner in our mission to modernize pathology through software and AI," said Dr. Andy Beck, co-founder and CEO of PathAI. "The deployment of AISight Dx across Labcorp's network brings high-quality, efficient digital pathology to a national scale."The expansion builds on Labcorp's 2019 strategic investment in PathAI, a collaboration that has since advanced to include AI-driven clinical trial support and validation of novel AI-pathology solutions.To learn more about Labcorp's digital pathology capabilities, visit https://www.labcorp.com/disciplines/digital-pathology-and-artificial-intelligence-aiAbout Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.1 AISight® Dx is FDA-cleared for primary diagnosis in the US and CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected deployment and benefits of the Path AI AISight Dx digital pathology platform.Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS










View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-expands-collaboration-with-pathai-to-deploy-fda-cleared-digital-pathology-platform-nationwide-302694248.htmlSOURCE Labcorp

Original: Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

Labcorp tops Q4 profit forecasts but revenue slightly missesFebruary 17, 2026 10:14 AM
IH Market News
Labcorp Holdings Inc. (NYSE:LH) delivered fourth-quarter adjusted earnings above expectations on Tuesday, though revenue came in marginally below Wall Street estimates as the diagnostics group closed out fiscal 2025.Shares were little changed in pre-market trading following the release.The Burlington, North Carolina-based company reported adjusted earnings per share of $4.07 for the quarter, exceeding analyst projections of $3.93. Revenue totaled $3.52 billion, just under the $3.56 billion consensus forecast. Compared with the same period last year, revenue increased 5.6% from $3.33 billion, while adjusted EPS rose 18% from $3.45.“In 2025, Labcorp grew revenue over 7% and delivered double-digit adjusted EPS growth, margin expansion and strong free cash flow. Performance was driven by continued strength in our Diagnostics and Central Laboratory businesses,” said Adam Schechter, Chairman and CEO of Labcorp.For full-year 2025, Labcorp posted revenue of $13.95 billion, up 7.2% from $13.01 billion in 2024. Annual adjusted earnings per share climbed to $16.44 from $14.57 the prior year.The Diagnostics Laboratories segment, the company’s largest division, generated fourth-quarter revenue of $2.73 billion, up 5.5% year over year. Adjusted operating margin for the segment improved to 15.4%, compared with 13.9% a year earlier.Looking ahead to fiscal 2026, Labcorp forecast adjusted earnings in a range of $17.55 to $18.25 per share, with the midpoint slightly above the analyst consensus of $17.52.The company expects enterprise revenue between $14.61 billion and $14.79 billion, implying midpoint growth of 5.4%.During the quarter, Labcorp expanded its network of health system and laboratory partnerships, completing several acquisitions, including selected outreach laboratory services from Parkview Health and anatomic pathology assets from Incyte Diagnostics.Labcorp Holdings stock price

Original: Labcorp tops Q4 profit forecasts but revenue slightly misses

Labcorp Announces 2025 Fourth Quarter and Full Year ResultsFebruary 17, 2026 6:50 AM
PR Newswire (US)

Company Provides 2026 GuidanceFinancial results from Operations versus 2024:Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billionDiluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billionProvided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4%Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9%Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8%Expanded partnerships with health systems and regional/local laboratories by signing or closing 13 transactions in 2025Advanced leadership in specialty testing, launching more than 130 innovative new tests in 2025, including in oncology, women's health, neurology and autoimmuneAnnounced strategic investment to build a modern, state-of-the-art 500,000 square foot Central Laboratory facility to address growth in demandBURLINGTON, N.C., Feb. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance.







"In 2025, Labcorp grew revenue over 7% and delivered double-digit adjusted EPS growth, margin expansion and strong free cash flow. Performance was driven by continued strength in our Diagnostics and Central Laboratory businesses," said Adam Schechter, Chairman and CEO of Labcorp. "We made significant progress across our strategic priorities, and we begin 2026 with strong momentum, and expect continued strong performance in 2026 as we remain focused on growth."In the fourth quarter of 2025, Labcorp advanced its position as a partner of choice for health systems and regional/local laboratories, expanding access to Labcorp's broad menu of routine and specialty tests and driving efficiencies for customers. In the quarter, Labcorp:Entered into an agreement to acquire select outreach laboratory services from Parkview Health.Completed the acquisition of select outreach assets from Community Health Systems.Completed the acquisition of select anatomic pathology assets from Incyte Diagnostics.Subsequent to quarter end, completed the acquisition of select assets of Empire City Laboratories.Throughout fourth quarter and subsequent to quarter end, the company continued to harness the power of science, technology and innovation:Launched the first FDA-cleared blood test for Alzheimer's disease assessment in primary care settings, enabling wider access, improving early evaluation and supporting timely patient care.Expanded access to its molecular residual disease (MRD) testing for stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer to help clinicians detect cancer recurrence earlier than traditional imaging.Launched several new consumer-initiated tests through Labcorp OnDemand, including tests for food allergies, micronutrients and thyroid health.Announced that it became the first U.S. commercial laboratory to enter an agreement to implement Roche's fully automated mass spectrometry solution.Announced a strategic investment to build a new state-of-the-art 500,000 square foot Central Laboratory facility in Indiana, with construction expected to begin later in 2026.On January 14, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on March 12, 2026, to stockholders of record at the close of business on February 27, 2026. In the quarter, Labcorp repurchased $225 million of common stock, resulting in full year total share repurchase of $450 million.LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED RESULTS
Three Months Ended Dec 31,
Year Ended Dec 31,

2025
2024
Delta
2025
2024
Delta













Revenue Summary (Dollars in billions)










Total Revenue$    3.52
$     3.33
5.6 %
$   13.95
$    13.01
7.2 %
Organic (1)



3.8 %




4.4 %
Acquisitions, net of Divestitures



1.2 %




2.5 %
Foreign Exchange



0.6 %




0.4 %













(1) Organic revenue is no longer separated between the Base Business and COVID-19 Testing.
Earnings Summary (Dollars in millions, except per share data)






Operating Income ("OI")$  267.6
$   216.5


$  1,384.7
$ 1,086.7


OI as % of Revenue7.6 %
6.5 %
110 bps
9.9 %
8.4 %
160 bps













Adjustments (2)$  220.1
$   206.7


$   616.9
$    710.3















Adjusted Operating Income  ("AOI") (3)$  487.7(4)$   423.2


$  2,001.6
$ 1,797.0


AOI as % of Revenue13.9 %(4)12.7 %
120 bps
14.3 %
13.8 %
50 bps













Net Earnings Attributable to Labcorp
Holdings Inc. $  164.7
$   143.4


$   876.5
$    746.0


Diluted EPS$    1.98
$     1.70


$   10.46
$      8.84


Adjusted EPS (3)$    4.07
$     3.45


$   16.44
$    14.57















(2) Adjustments include amortization, impairment charges, restructuring charges, and special items.
(3) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.
(4) The increase in adjusted operating income and margin was primarily driven by organic growth in Diagnostics
 and Central Labs.
 LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED RESULTS
Three Months Ended Dec 31,
Year Ended Dec 31,
2025
2024
2025
2024Cash Flow Summary (Dollars in millions)














Operating Cash Flow$          614.2
$          777.2
$      1,640.5
$      1,585.8Capital Expenditures123.9
112.1
434.5
489.9Free Cash Flow$          490.3(1)$          665.1
$      1,206.0
$      1,095.9







(1) The decrease in free cash flow was primarily driven by working capital timing.Capital Allocation SummaryAt the end of the quarter, Labcorp's cash and cash equivalents balance was $532.3 million and total debt was $5.58 billion.During the quarter, the company invested $258.0 million in acquisitions, paid out $59.3 million in dividends, and repurchased $225.0 million of stock.During the year, the company invested $582.0 million in acquisitions, paid out $240.7 million in dividends, and repurchased $450.0 million million of stock.LABCORP HOLDINGS INC.
Diagnostics Laboratories Segment Summary
Three Months Ended December 31,
2025
2024
DeltaRevenue Summary (Dollars in billions)




Total Revenue$          2.73
$      2.59
5.5 %Organic (1)



4.1 %Acquisitions, net of Divestitures



1.5 %





(1) Organic revenue is no longer separated between the Base Business and COVID-19 Testing.





Earnings Summary (2) (Dollars in millions)



Adjusted Operating Income ("AOI") (3)$        419.2
$    359.5

AOI as % of Revenue15.4 % (4)13.9 %
150 bps





(2) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.(3) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.(4) Adjusted operating margin increased primarily driven by organic growth, which includes Invitae. 
Three Months Ended Dec 31,
2025
Requisition
Price/Mix
Volume Delta (5)
Delta (5)Metrics Summary


Total2.2 %
3.3 %Organic (6)1.1 %
3.0 %Acquisitions, net of Divestitures1.1 %
0.3 %Foreign Exchange— %
— %



(5) Column shows changes versus the three months ended December 31, 2024.(6) Organic price/mix includes lab management agreements. LABCORP HOLDINGS INC.
Biopharma Laboratory Services Segment Summary
Three Months Ended December 31,

2025
2024
Delta
Revenue Summary (Dollars in millions)




Total Revenue$        793.0
$        767.0
3.4 %(1)Organic



0.6 %
Foreign Exchange



2.8 %







(1) Central Labs revenue growth of 11.1%; Early Development revenue was down 13.5%.






Earnings Summary (2) (Dollars in millions)




Adjusted Operating Income ("AOI") (3)$        136.1(4)$        130.8


AOI as % of Revenue17.2 %
17.0 %
10 bps(4)






(2) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.(3) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.(4) Adjusted operating income was slightly up due to Central Labs revenue growth. 
As of December 31,

2025
Metrics Summary (Dollars in billions)

TTM Net Orders$                                         3.37
TTM Book-to-Bill1.09
Backlog$                                         8.72(5)Next Twelve Months Forecast Backlog Conversion$                                         2.66



(5) Backlog increased 9.2% compared to this period last yearGuidance for 2026The following guidance assumes foreign exchange rates effective as of December 31, 2025, for the full year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.(Dollars in billions, except per share data)




Results
2026 Guidance





2025
LowHighRevenue



Labcorp Enterprise (1)(2)$13.95
4.7 %6.0 %Diagnostics Laboratories (3)$10.88
5.0 %6.0 %Biopharma Laboratory Services (4)$3.10
3.0 %5.0 %









Adjusted EPS$16.44
$17.55$18.25




Free Cash Flow$1.21
$1.24$1.36




(1) 2026 Guidance includes an impact from foreign currency translation of 0.4%.(2) Enterprise level revenue is presented net of intercompany transaction eliminations.(3) 2026 Guidance includes an impact from foreign currency translation of 0.1%.(4) 2026 Guidance includes an impact from foreign currency translation of 1.7%.Use of Adjusted MeasuresThe company has provided in this press release and accompanying tables "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company's operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company's financial results with the financial results of other companies. However, the company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and an identification of the components that comprise "special items" used for certain adjusted financial information are included in the tables accompanying this press release.The company today is providing an investor relations presentation with additional information on its business and operations, which is available in the investor relations section of the company's website at www.Labcorp.com. Analysts and investors are directed to the website to review this supplemental information.A conference call discussing Labcorp's quarterly results will be held today at 9:00 a.m. ET and is available by registering at this link, which will provide a dial-in number and unique PIN to access the call. It is recommended that participants join 10 minutes prior to the start of the call, although participants may register and join at any time during the call. A live webcast of Labcorp's quarterly conference call on February 17, 2026, will be available at the Labcorp Investor Relations website beginning at 9:00 a.m. ET. This webcast will be archived and accessible through February 4, 2027.About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including global economic and market conditions  on the company's businesses, operating results, cash flows and/or financial condition, (iii) future business  strategies, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions and partnerships, and (v) opportunities for future growth.Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company's former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failure of the company's information technology, systems, or data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xviii) the number of revenue days in a financial period; (xiii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward- looking statements.The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".- End of Text -
- Tables to Follow - LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Millions, Except Per Share Data)
Three Months Ended
December 31,
Year Ended December
31,
2025
2024
2025
2024Revenues$    3,515.8
$    3,329.4
$ 13,951.7
$ 13,008.9Cost of revenues2,522.6
2,433.1
9,939.2
9,384.5Gross profit993.2
896.3
4,012.5
3,624.4Selling, general, and administrative expenses538.6
595.2
2,216.3
2,230.0Amortization of intangibles and other assets72.6
70.4
280.0
256.4Goodwill and other asset impairments3.6
2.8
4.3
5.3Restructuring and other charges110.8
11.4
127.2
46.0Operating income267.6
216.5
1,384.7
1,086.7Other (expense) income:






Interest expense(55.0)
(63.4)
(224.1)
(208.3)Investment income3.5
15.0
15.2
22.3Equity method loss, net(6.1)
(0.7)
(13.3)
(1.4)Other, net(19.4)
16.4
(55.0)
60.2Earnings from operations before income taxes190.6
183.8
1,107.5
959.5Provision for income taxes25.7
40.2
229.8
212.4Net earnings164.9
143.6
877.7
747.1Less: Net earnings attributable to the noncontrolling interest(0.2)
(0.2)
(1.2)
(1.1)Net earnings attributable to Labcorp Holdings Inc.$       164.7
$       143.4
$       876.5
$       746.0







Earnings per common share:






   Basic earnings per common share$         2.00
$         1.72
$       10.54
$         8.89   Diluted earnings per common share$         1.98
$         1.70
$       10.46
$         8.84







Weighted-average basic common shares outstanding82.5
83.6
83.2
83.9Weighted-average diluted common shares outstanding83.2
84.2
83.8
84.4 LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In Millions)
December 31,
2025
2024ASSETS


Current assets:


Cash and cash equivalents$                532.3
$           1,518.7Accounts receivable, net2,103.8
1,944.1Unbilled services, net156.9
152.9Supplies inventory534.7
493.2Prepaid expenses and other692.8
697.6Total current assets4,020.5
4,806.5Property, plant, and equipment, net3,081.5
3,045.4Goodwill, net6,789.5
6,369.7Intangible assets, net3,596.0
3,488.9Joint venture partnerships and equity method investments153.9
16.3Other assets, net751.3
652.2Total assets$           18,392.7
$         18,379.0LIABILITIES AND SHAREHOLDERS' EQUITY


Current liabilities:


Accounts payable$                840.8
$              875.8Accrued expenses and other847.8
871.2Unearned revenue439.1
392.2Short-term operating lease liabilities191.1
184.6Short-term finance lease liabilities4.6
6.1Short-term borrowings and current portion of long-term debt500.1
1,000.3Total current liabilities2,823.5
3,330.2Long-term debt5,084.6
5,331.2Operating lease liabilities682.6
676.3Financing lease liabilities63.0
74.3Deferred income taxes and other tax liabilities454.5
383.1Other liabilities647.8
517.4Total liabilities9,756.0
10,312.5Commitments and contingent liabilities


Noncontrolling interest16.9
14.3Shareholders' equity:


Common stock, 82.2 and 83.4 shares outstanding at December 31, 2025, and
2024, respectively7.5
7.6Additional paid-in capital—
2.8Retained earnings8,639.9
8,303.4Accumulated other comprehensive loss(27.6)
(261.6)Total shareholders' equity8,619.8
8,052.2Total liabilities and shareholders' equity$           18,392.7
$         18,379.0 LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Millions)
Three Months Ended
December 31,
Year Ended
December 31,
2025
2024
2025
2024CASH FLOWS FROM OPERATING ACTIVITIES:






Net earnings$    164.9
$    143.6
$    877.7
$    747.1Adjustments to reconcile net earnings to net cash provided by operating activities:






Depreciation and amortization173.0
170.6
681.1
643.5Stock compensation29.7
27.3
125.8
116.7Operating lease right-of-use asset expense 59.0
48.6
208.1
185.3Goodwill and other asset impairments3.6
2.8
4.3
5.3Non-cash portion of Restructuring and other charges101.3
—
101.3
—Deferred income taxes21.2
38.5
97.6
(20.1)Other, net19.0
16.1
70.7
62.1Change in assets and liabilities (net of effects of acquisitions and divestitures):






Decrease (increase) in accounts receivable4.9
90.9
(125.5)
(52.3)(Increase) decrease in unbilled services(0.6)
7.6
3.3
30.4(Increase) decrease in supplies inventory(12.3)
(14.6)
(30.2)
(12.6)Increase in prepaid expenses and other(41.0)
(14.7)
(25.2)
(54.5)Increase (decrease) in accounts payable151.6
210.3
(52.8)
72.1Increase (decrease) in unearned revenue47.2
3.3
34.6
(24.6)(Decrease) increase in accrued expenses and other(107.3)
46.9
(330.3)
(112.6)Net cash provided by operating activities614.2
777.2
1,640.5
1,585.8CASH FLOWS FROM INVESTING ACTIVITIES:






Capital expenditures(123.9)
(112.1)
(434.5)
(489.9)Proceeds from sale of assets4.5
1.4
8.0
2.0Proceeds from sale or distribution of equity affiliates or other investments—
—
6.9
—Purchase of equity affiliates or other investments(12.5)
(12.7)
(192.4)
(55.0)Proceeds from sale of business—
1.6
—
15.1Acquisition of businesses, net of cash acquired(258.0)
(87.8)
(582.0)
(839.0)Net cash used for investing activities(389.9)
(209.6)
(1,194.0)
(1,366.8)CASH FLOWS FROM FINANCING ACTIVITIES:






Proceeds from revolving credit facilities—
—
64.8
2,463.7Payments on revolving credit facilities—
—
(64.8)
(2,463.7)Proceeds from accounts receivable securitization—
—
225.0
300.0Proceeds from senior note offerings—
—
—
2,000.0Payments on senior notes—
(400.0)
(1,000.0)
(1,000.0)Net share settlement tax payments from issuance of stock to employees(1.3)
(7.7)
(31.9)
(46.4)Net proceeds from issuance of stock to employees—
3.2
54.3
56.2Dividends paid(59.3)
(60.1)
(240.7)
(243.1)Purchase of common stock(225.0)
(75.1)
(450.0)
(250.1)Other, net(4.8)
(7.0)
(13.7)
(36.7)Net cash (used for) provided by financing activities(290.4)
(546.7)
(1,457.0)
779.9Effect of exchange rate changes on Cash and cash equivalents0.3
(19.5)
24.1
(17.0)Net (decrease) increase in Cash and cash equivalents(65.8)
1.4
(986.4)
981.9Cash and cash equivalents at beginning of period598.1
1,517.3
1,518.7
536.8Cash and cash equivalents at end of period$    532.3
$ 1,518.7
$    532.3
$ 1,518.7 LABCORP HOLDINGS INC. AND SUBSIDIARIES
Condensed Combined Non-GAAP Segment Information
(Dollars in Millions)
Three Months Ended
December 31,
Year Ended 
December 31,
2025
2024
2025
2024Diagnostics Laboratories






Revenues$       2,728.5
$       2,586.2
$     10,876.5
$     10,144.3







Adjusted operating income$           419.2
$           359.5
$       1,779.9
$       1,606.3Adjusted operating margin15.4 %
13.9 %
16.4 %
15.8 %







Biopharma Laboratory Services






Revenues$           793.0
$           767.0
$       3,098.2
$       2,922.6







Adjusted operating income$           136.1
$           130.8
$           498.5
$           458.9Adjusted operating margin17.2 %
17.0 %
16.1 %
15.7 %







Consolidated






Revenues$       3,515.8
$       3,329.4
$     13,951.7
$     13,008.9







Adjusted segment operating income$           555.3
$           490.3
$       2,278.4
$       2,065.2Unallocated corporate expense(67.6)
(67.1)
(276.8)
(268.2)Consolidated adjusted operating income$           487.7
$           423.2
$       2,001.6
$       1,797.0Consolidated adjusted operating margin13.9 %
12.7 %
14.3 %
13.8 %The consolidated revenue and adjusted segment operating income are presented net of intercompany transaction eliminations and other amounts not used in determining segment performance. Adjusted operating income and adjusted operating margin are non-GAAP measures. See the subsequent reconciliation of non-GAAP financial measures.LABCORP HOLDINGS INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
(Dollars and Shares in Millions, Except Per Share Data)

Three Months Ended
December 31,
Year Ended December
31,

2025
2024
2025
2024Adjusted Operating Income







Operating income
$     267.6
$     216.5
$  1,384.7
$  1,086.7Amortization of intangibles and other assets (a)
72.6
70.4
280.0
256.4Restructuring and other charges (b)
110.8
11.4
127.2
46.0Acquisition and disposition-related (income) costs (c)
(2.1)
51.3
52.9
146.4Launchpad costs (d)
13.1
7.0
64.1
65.7Asset impairments (e)
3.6
2.8
4.3
5.3Customer and vendor cyber-event costs  (f)
0.3
16.8
1.7
24.1Other
21.8
30.7
82.9
86.4TSA Reimbursement (g)
—
16.3
3.8
80.0Adjusted operating income
$     487.7
$     423.2
$  2,001.6
$  1,797.0








Adjustments impacting revenues
$           —
$       15.0
$           —
$       15.0








Adjusted operating profit margin
13.9 %
12.7 %
14.3 %
13.8 %








Adjusted Net Income







Net income
$     164.7
$     143.4
$     876.5
$     746.0Impact of adjustments to operating income
220.1
206.7
616.9
710.3Losses on venture fund investments, net (h)
10.2
4.1
44.1
11.4Equity method loss from SYNLAB investment(i)
5.8
—
10.8
—Gain on sale of business (j)
—
(1.5)
—
(6.4)Pension settlement (k)
11.1
(2.3)
11.1
—TSA reimbursement (g)
—
(16.3)
(3.8)
(80.0)Other
(0.2)
—
0.6
0.3Income tax impact of adjustments (l)
(72.8)
(43.7)
(179.0)
(151.3)Adjusted net income
$     338.9
$     290.4
$  1,377.2
$  1,230.3








Weighted average diluted shares outstanding
83.2
84.2
83.8
84.4








Adjusted net income per share
$       4.07
$       3.45
$     16.44
$     14.57

(a)Amortization of intangible assets acquired as part of business acquisitions.(b)Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions and facilities and contract termination costs within the organization in connection with our LaunchPad initiatives, and acquisitions or dispositions of businesses by the company, and are inclusive of the actions taken in Early Development.(c)Acquisition and disposition-related (income) costs include due-diligence legal and advisory fees, retention bonuses, impact of delayed contract or license transfers, purchase price adjustments, and other integration or disposition related activities.  The three and twelve months ended December 31, 2025 includes acquisition purchase price reductions of $17.0 million.(d)LaunchPad costs include non-capitalized costs associated with the implementation of systems, consolidation of processes, and consulting costs incurred as part of various business process improvement initiatives.(e)The company impaired certain fixed assets which are no longer realizable by the business.(f)The company incurred cost and additional collection reserves as the result of customer and vendor cyber events.(g)Represents transition services fees charged to Fortrea Holdings Inc. related to administrative and IT systems support.  The costs to provide these services are included in operating income but the service fees are included in other income.(h)The company makes investments in companies or investment funds developing promising technology related to its operations. The company recorded net gains and losses related to several distributions from venture funds, increases in the market value of investments, and impairments of other investments due to the underlying performance of the investments.(i)Adjustment removes the impact of the equity method income from the Company's minority investment in SYNLAB.(j)The company recorded a gain on the disposition of the Beacon Laboratory Benefits Solutions business.(k)The company incurred a charge related to its U.S. pension plan due to settlement of certain obligations to retired employees.(l)Income tax impact of adjustments calculated based on the tax rate applicable to each item. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-2025-fourth-quarter-and-full-year-results-302689090.htmlSOURCE Labcorp Holdings Inc

Original: Labcorp Announces 2025 Fourth Quarter and Full Year Results

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary CareFebruary 11, 2026 7:00 AM
PR Newswire (US)

Elecsys® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathologyNow available nationwide in primary care settings for patients aged 55 and older experiencing symptoms of cognitive declineExpands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests across both primary and specialty care settingsBURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment of Alzheimer's disease in the primary care setting. This launch further expands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests, offering clinicians solutions across both primary and specialty care settings.







"Primary care clinicians are often the first point of contact for patients with concerns related to cognitive symptoms, yet Alzheimer's testing has historically required a visit to a specialist," said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. "By making this first-of-its-kind blood test available nationwide, Labcorp is giving primary care clinicians a powerful tool to help patients get answers sooner and guide next steps with confidence."The Elecsys pTau-181 test helps clinicians rule out Alzheimer's disease by identifying which symptomatic patients aged 55 and older are unlikely to have amyloid pathology—abnormal protein buildup in the brain associated with Alzheimer's disease—in the context of all clinical findings. Patients with negative results can be evaluated for other potential causes of cognitive decline, while patients with positive results can be referred for additional testing. The test was developed by Roche Diagnostics and cleared by the FDA in 2025.Key Benefits of the Elecsys pTau-181 Test:Offers 97.9% negative predictive value, helping clinicians more confidently rule out Alzheimer's pathology in symptomatic patientsIs performed via a simple blood draw, which can be completed in a doctor's office or at any of Labcorp's more than 2,200 patient service centers nationwideProvides an alternative to traditional approaches that require brain scans or lumbar punctures, which can be costly, invasive or difficult to accessHelps reduce unnecessary referrals amid a national shortage of neurologists, supporting timely evaluation of other causes of cognitive declineLabcorp's Commitment to Innovative Alzheimer's Testing
With an estimated 7.2 million Americans living with Alzheimer's disease, Labcorp is committed to expanding access to blood-based biomarkers that support earlier assessment and diagnosis. The Elecsys pTau-181 test strengthens Labcorp's portfolio of blood-based biomarker tests for Alzheimer's disease and other forms of dementia. To learn more, visit: https://www.labcorp.com/treatment-areas/neurology-based biomarker tests for Alzheimer's disease andLabcorp's deep expertise in Alzheimer's biomarkers extends into therapeutic development, supporting more than 90 Alzheimer's disease protocols across more than 45 countries over the last five years. To learn more, visit: https://www.labcorp.com/treatment-areas/neurology/biomarker-developmentAbout Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.



View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-first-fda-cleared-blood-test-for-alzheimers-disease-assessment-in-primary-care-302684545.htmlSOURCE Labcorp

Original: Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of DirectorsFebruary 9, 2026 8:30 AM
PR Newswire (US)

BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026.







Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical research, medical education and large-scale health system leadership. He also has deep expertise in oncology, neuroscience, women's health and personalized medicine which aligns with Labcorp's strategic areas of focus."John is widely respected as a leader in academic medicine, clinical practice, health system strategy and research," said Adam Schechter, Chairman and Chief Executive Officer of Labcorp. "His expertise will help advance Labcorp's strategy across diagnostics and drug development and enhance the value we deliver to customers."Before joining the CU Anschutz School of Medicine, Dr. Sampson held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease."Labcorp plays a critical role in advancing earlier diagnosis, personalized medicine and the development of new therapies," said Dr. Sampson. "I look forward to contributing my clinical and research experience to help further the company's mission of improving health and improving lives."In connection with Dr. Sampson's appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee.About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.










View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-appoints-john-h-sampson-md-phd-to-board-of-directors-302682096.htmlSOURCE Labcorp Holdings Inc

Original: Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

LH anew 52=Week high

LH new 52 week high

Before I bounce

For another trip

Watching to see if she'll give back

Had to take profits here! Loved this stock ... still do but. Got to take dat money

BREAKING NEWS: $LH How to Trade Laboratory Corporation $LH With Risk Controls

Price matters most to making money in the market. Celebrating 20 years, Stock Traders Daily provides the tools that help you develop investment strategies, and this is a good example. When we couple this with out market based analysis, the probabilities of going with the flow increases, and t...

Got this from LH - How to Trade Laboratory Corporation $LH With Risk Controls

Waiting for this to GO LOWER NOW on vaccine related developments. Folks don't realize this is a GOOD development for LH too! Since they suffered BADLY from folks NOT wanting to get their NORMAL tests done, visit Dr's offices, etc., when COVID first arrived & business suffered (along with the stock price).

Just wait,... like me, & ACCUMULATE LOWER.... Better days ahead AGAIN!

DAY JUST KEEPS GETTING BETTER! ALL my stocks are WINNERS!!

Bringing home the BACON!! Boo-yah!

Climbing RIGHT BACK to $200+ from $182's & 183's recently...

CONGRATS to those who follow along & BOUGHT IT WITH ME!! GLA

#MoneyMaker!

Already UP $5.00 from yesterday's BUYS eh? I LIKE IT!

Keep it rolling LH! LOVE making that CASH MONEY!

THANK YOU for the $182's & $183's BABY! Morning is ALREADY off to a GREAT START!! Stalking & preying! Thank you LH... Taking the low & sub-$180's as a gift here in the short-term.

Danka!

Almost, getting warmer & kinda closer... Keep sliding down. You can DOOOO IT!

A BIT FURTHER & I'll be a very happy camper.

Come back to PAPA baby! You KNOW I love me some sub-$190 reloads as the NEXT STEP is a hearty break up OVER $200 imv...

Take those $185's like I robbed those sub-$170's from last month!

Gift that keeps on a givin'!

$196 & CLIMBING!! Should see pre-Market $200.00 pretty soon!

I LOVE ALL MY STOCKS!! xoxoxox

If I have powder this gets bought at any level below 200. IMO; the feds running out of money, we're on traders now not fed money, may move like a snail for awhile! BA

$194 baby weeeee..... LMAO... Just enjoying the ride is all. This one took a bit LONGER than I thought to breakout but,... It's all good with these institutional stocks!

LH 50/200sma had a bullish golden cross here...Nice long term bullish sign...

$183... Weeeeee.... LOL with MORE TO COME!

COMING UP on 3-mo highs here!!

Undervalued... ALL I'm saying! See you higher bud.

$180.- with CALLS looking GOODIE!! Ha ha & my LAST BUYS were $167-$168!!

So happy! Weeeee..... LabCorp just keeps on plugging away, executing & releasing UNDERESTIMATED NEWS in terms of their overall business strategy!

Personalized medicine & PERSONALIZED clinical trials, serving drug companies MORE EFFICIENTLY with 50+ years of DATA MINING using A.I. & other metrics means COVANCE is going to SCALE NEW PHARMA business MUCH MORE quickly than ANYONE expects. LabCorp corona-pause has been a GREAT development as telemed, telehealth & MORE EFFICIENT modalities (including clinical synergies) are developed, adopted & ACCELERATED far faster than what would have been ORGANIC without covid...imho!

BUY, BUY, & BIG TABLE POUNDING BUY!!

Still buying BA on dipos, see better ROI. I own what I own here, not looking to buy more. I like gmbl even with the run.

Institutional ownership here has buys kinda DOW-tied. This stock dropping BELOW that 200DMA would likely have a SERIOUS DOW TEST lower!

I know, I accidentally had an order in @ $167.00 when it dropped on the 27th. I went to put an ORDER just at or slightly above the 200DMA that day & realized I had a 300 share limit order in there from the 21st that was executing.

If the stock had the KIND OF WEAKNESS you're suggesting it would have TESTED that 200DMA right then & there! And TECHNICALLY it kinda should have...

The DOW performance on this MOSTLY institutionally-owned STOCK is KEY here imv,... If the DOW stays sideways or moves higher I don't see LH taking a dive UNLESS some directly negative news event happens.

Everything is tailwind right now with CORONAVIRUS ramp-up, with country getting back to normal, with economy re-opening, travel coming back, the advances in telemed, the NEW Medable deal, etc., etc., etc..
https://finance.yahoo.com/news/labcorp-partners-medable-expand-technology-132901628.html


By next Q, there's talk LH may even GET AHEAD of U.S. corporate & announce a dividend. It'd SHOCK the market & shoot LH into the $220 range for sure imho. But even without that they should be doing well enough to see $200 test into Q3 before long. I think there's a BETTER SHOT @ a $200 test than that $120 or whatever you were hoping to buy here... I just don't see it falling that far without some SERIOUS issue or market-wide event/pressure.

We don't break through 180 early next week we're going down. But the RSI IS AT 51.

Setting up nicely AS OUTLINED!! Price target ACQUIRED...Now let's see what we see... $$$

(edit) DANG that close dropped us RIGHT OUT of that sweet spot!

Just had a LOVELY RE-TEST of the bottom-uptrend CHANNEL @ $172.75 & NOW I'm EXPECTING MORE UPSIDE gains!!


Trump about to speak, let's hope it's NOTHING STUPID! Gotta see that $175.63 break before close imho!

Next week has HUGE PROMISE if we close up North & again,...NOTHING DUMB happens out there... We COULD see a BIG BREAK above $179 next week. Too bad the options here aren't as plentiful & more reasonably priced with TIGHTER SPREADS because it'd be a GREAT R/R upcoming!

I'm plugging BA

$LH just quietly PLUGGING ALONG higher! Looking like $180+ is a CALLING!!


LH

PRETTY AMAZING CALL if I say so myself. Came down just BEFORE that MA & then LAUNCHED right into $175 close!!

Been SMOKING HOT lately...

Might test $165 50DMA before BREAKING UP through $175 range into pre-COVID ~$196.+ highs... IF it does I'll be a buyin' it back right theeere BIGGLY. Meantime, I just re-took a starter to build upon since I'm fairly certain it's going to that $175-level sooner rather than later.

With COVID testing at all-time highs AND back-to-work efforts puts LH right in the thick of BOTH circumstances! People getting back to normalcy means regular testing, Dr. appts, etc., = improved business AND C-19 ramp-up means MO BUSINESS TOO! Can't lose, going forward.

May be way some price targets have been RAISED on the stock to $244.00++

Meanwhile we're POPPING UUUUP, UP in here...

BOING set to pop higher. No one knows if 2nd-wave (covid-19) FEARS will materialize in ANY meaningful way; however, I expect BA to recover just under 50% of pre-Covid highs by the end of the year & demonstrably so from September (into Holidays as we move into the New Year).

As mentioned to YOU before: I don't make ANY specific calls to others because YOU NEVER know what their level of EXPERIENCE investing is. But MORE IMPORTANTLY, their REASONS for investing, goals, timelines, etc.. & sometimes that's MORE IMPORTANT than what they're investing in &/or ought to INFORM what, how, when, etc..



I chart, study fundamentals, macro developments & have a VERY HEALTHY & ROBUST RISK tolerance so I take MORE chances than many. And those choices tend towards being VERY CALCULATED. Not always, but that's the goal. And what's right for me, may not be for a retiree, new investor, etc.. They may NOT even have tools & skills to write calls or puts for example & make money (or reduce losses) if an investment goes sideways, the market turns against them, COVID-2 happens or whatever... So MY POSTS, decisions & DECLARATIONS are more to keep MYSELF honest. Hey, I bought this @ this time, see this, etc.. & act accordingly. MOSTLY in real time. You don't see alot of that on these boards... But I think its the ONLY way to evaluate my trading. GL

Tommy, how far is the BA gonna run, seems like better use

ANOTHER GREAT Chartastic pick-up over less than 24hrs... $164 gap-fill & NOW a few hours later (in trading terms) we're DRIVING UP through $173.50+ & hit $173.84 already.

BUY the DIPS,...been SHOUTING this TABLE POUNDING BUY for quite awhile now! Pre-Covid $196.36 highs should be on the radar by Q3 for sure!

LH is a BIG BUY!